Photoimmunotherapy (PIT) is an investigational, precision-based cancer-treatment platform, currently under development by Rakuten Medical. It is comprised of a drug and device combination that utilizes monoclonal antibodies conjugated to a dye (IRDye® 700DX). Illumination of the tumor with non-thermal red light (690 nm) is believed to result in anti-cancer activity, which is mediated by biophysical processes that may compromise the membrane integrity of cells. The targeted binding of antibody-IR700 conjugate to a specific antigen and subsequent illumination is believed to result in rapid and selective cell killing and tumor necrosis with minimal effects on surrounding normal tissue. PIT may also lead to the systemic induction of innate and adaptive immunity.